NAMUH, an infant nutrition company, and Ginkgo Bioworks announced a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those found in human breast milk. Human Milk Oligosaccharides, or HMOs, are essential fiber-like nutrients unique to human milk that provide an important energy source to beneficial gut bacteria in infants. Despite being the third most abundant component in human milk, HMOs are currently a small component in infant formulas, if present at all. Currently, NAMUH’s proprietary technology provides for a cost-effective source of a family of HMOs via yeast fermentation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks, Xwell expand support for CDC’s Genomic Surveillance program
- Ginkgo Bioworks and Xwell partner in influenza variant detection for CDC
- Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review
- Ginkgo Bioworks backs FY22 revenue view $460M-$480M, consensus $470.79M
- Ginkgo Bioworks, Prokarium announce RNA collaboration